Although immunohistochemical analysis revealed that PSMA expression in the endothelial cells of the neovasculature may vary depending on patients, our results suggest that the PSMA-EV measurement would be useful for diagnosis and monitoring of RCC patients and possibly for evaluation of anti-angiogenic agents such as tyrosine-kinase inhibitors. The gene discussed is FOLH1; the disease is renal cell carcinoma.